Ryan Watts Sells 35,198 Shares of Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan Watts sold 35,198 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the sale, the chief executive officer directly owned 296,833 shares in the company, valued at $4,897,744.50. This trade represents a 10.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Denali Therapeutics Price Performance

DNLI traded up $0.12 during trading hours on Thursday, hitting $17.07. The company’s stock had a trading volume of 1,756,635 shares, compared to its average volume of 1,845,314. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of -5.87 and a beta of 1.05. Denali Therapeutics Inc. has a 12 month low of $10.57 and a 12 month high of $24.34. The company has a current ratio of 9.79, a quick ratio of 9.79 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $17.32 and its 200-day moving average price is $15.63.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. During the same quarter in the previous year, the firm earned ($0.63) EPS. The company’s revenue was up .0% on a year-over-year basis. Sell-side analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Institutional Trading of Denali Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Denali Therapeutics by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 11,992,918 shares of the company’s stock worth $174,137,000 after buying an additional 182,183 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Denali Therapeutics by 88.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company’s stock valued at $91,996,000 after purchasing an additional 3,184,042 shares during the last quarter. Norges Bank acquired a new stake in shares of Denali Therapeutics in the second quarter valued at approximately $55,224,000. Alliancebernstein L.P. raised its holdings in shares of Denali Therapeutics by 12.2% in the third quarter. Alliancebernstein L.P. now owns 3,520,414 shares of the company’s stock worth $51,116,000 after acquiring an additional 383,274 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Denali Therapeutics by 4.4% in the 2nd quarter. Geode Capital Management LLC now owns 3,172,305 shares of the company’s stock worth $44,386,000 after acquiring an additional 135,129 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on DNLI shares. Wedbush lowered their price objective on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Thursday, December 11th. Stifel Nicolaus set a $37.00 price objective on Denali Therapeutics in a report on Monday, November 17th. JPMorgan Chase & Co. boosted their price objective on shares of Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. UBS Group assumed coverage on shares of Denali Therapeutics in a research note on Wednesday. They set a “buy” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $32.77.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.